Draft:Zhejiang Hisun Pharmaceutical

Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

Retrieved on: 
Thursday, January 28, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemistry, Chemical compounds, Physical sciences, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Coronavirus disease, Antiviral drug, Draft:Zhejiang Hisun Pharmaceutical, Appili’s Phase 3 PRESECO Clinical Trial, Favipiravir, Appili Therapeutics

PRESECO is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.

Key Points: 
  • PRESECO is evaluating favipiravir, an oral antiviral, in the early treatment of COVID-19 in the outpatient setting.
  • Our PRESECO study is designed to answer the critical question, does favipiravir work for COVID-19 patients early in the outpatient setting?
  • Appili plans to prioritize its resources to accelerate recruitment and data analysis for the PRESECO study.
  • As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral favipiravir for the worldwide treatment and prevention of COVID-19.

Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Interim Order

Retrieved on: 
Tuesday, December 22, 2020
Health, Infectious diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Chemistry, Health sciences, Physical sciences, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Coronavirus disease, COVID-19 drug repurposing research, Draft:Zhejiang Hisun Pharmaceutical, Dr. Reddy’s, FUJIFILM Corporation, Global Response Aid (GRA):, AiPharma:, Appili Therapeutics:

If approved, we look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.

Key Points: 
  • If approved, we look forward to launching this important product soon to benefit the lives and health of COVID-19 patients in Canada.
  • Our role remains to design rigorous trials to obtain the data that identify COVID-19 patients that may benefit from REEQONUS.
  • Our outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation.
  • According to Health Canada, REEQONUS (favipiravir) Tablets are the first oral solid dosage form submitted under the Interim Order.

Chipscreen and HISUN reach a strategic cooperation

Retrieved on: 
Wednesday, December 16, 2020
BSE SENSEX, NIFTY 50, Sun Pharma, Medication, Life sciences, Draft:Zhejiang Hisun Pharmaceutical

SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation.

Key Points: 
  • SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation.
  • Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded inShenzhenon 2001, specializing in the research and development of novel small molecule drugs.
  • HISUN PHARMACEUTICAL has developed into a "pharmaceutical industry group" composed of business including raw materials, preparations, biological drugs, innovative drugs, and commercial distribution.
  • HISUN PHARMACEUTICAL's R&D and drug development covers therapeutic fields including oncology, anti-infection, cardiovascular, endocrine, immunosuppression, anti-depression, and orthopedics.

Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19

Retrieved on: 
Friday, October 30, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Other Health, Health sciences, Medicine, Chemistry, COVID-19, Ebola, Favipiravir, Hydroxyarenes, Isomerism, Pyrazines, Preventive healthcare, Post-exposure prophylaxis, Draft:Zhejiang Hisun Pharmaceutical, Avigan® (favipiravir), Appili Therapeutics, Dr. Reddy’s, Global Response Aid, FUJIFILM Toyama Chemical Co.

The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.

Key Points: 
  • The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.
  • The clinical development strategy will focus on evaluating Avigan tablets for early treatment and post-exposure prophylaxis in the community setting.
  • In collaboration with its partners, Appili will design and oversee Phase 3 clinical trials to support regulatory submissions worldwide.
  • In addition, the Company is also testing FUJIFILM Toyama Chemical Inc.s drug Avigan for the potential treatment and prevention of COVID-19.